1. Introduction
1.1 Business Market Insights Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:
4. Europe Next-generation Antibody Market Landscape
4.1 Market Overview
4.2 Porter's Five Forces Analysis
- 4.2.1 Bargaining Power of Suppliers
- 4.2.2 Bargaining Power of Buyers
- 4.2.3 Threat of New Entrants
- 4.2.4 Competitive Rivalry
- 4.2.5 Threat of Substitutes
4.3 Ecosystem Analysis
- 4.3.1 Raw Material Suppliers
- 4.3.2 Manufacturers
- 4.3.3 Distributors/Suppliers
- 4.3.4 End Users
5. Europe Next-generation Antibody Market – Key Market Dynamics
5.1 Growth Drivers
- 5.1.1 Breakthroughs in antibody development
- 5.1.2 Increase in demand for targeted therapies
5.2 Market Opportunities
- 5.2.1 Potential for next-gen antibodies in cancer immunotherapy
- 5.2.2 Expanding use of antibodies in rare disease treatments
5.3 Future Trends
- 5.3.1 Development of more targeted therapies
- 5.3.2 Growth in antibody-based treatments
5.4 Impact of Drivers and Restraints
6. Europe Next-generation Antibody Market Regional Analysis
6.1 Europe Next-generation Antibody Market Overview
6.2 Europe Next-generation Antibody Market Revenue 2019-2028 (US$ Million)
6.3 Europe Next-generation Antibody Market Forecast Analysis
7. Europe Next-generation Antibody Market Analysis – by Therapeutic Area
7.1 Oncology
- 7.1.1 Overview
- 7.1.2 Oncology: Europe Next-generation Antibody Market – Revenue and Forecast to 2031 (US$ Million)
7.2 Autoimmune or Inflammatory
- 7.2.1 Overview
- 7.2.2 Autoimmune or Inflammatory: Europe Next-generation Antibody Market – Revenue and Forecast to 2031 (US$ Million)
8. Europe Next-generation Antibody Market Analysis – by Technology
8.1 Antibody-drug conjugates
- 8.1.1 Overview
- 8.1.2 Antibody-drug conjugates: Europe Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
8.2 Bispecific antibodies
- 8.2.1 Overview
- 8.2.2 Bispecific antibodies: Europe Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
8.3 Fc engineered antibodies
- 8.3.1 Overview
- 8.3.2 Fc engineered antibodies: Europe Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
8.4 Antibody fragments & antibody-like proteins
- 8.4.1 Overview
- 8.4.2 Antibody fragments & antibody-like proteins: Europe Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
8.5 Biosimilar antibody products
- 8.5.1 Overview
- 8.5.2 Biosimilar antibody products : Europe Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
9. Europe Next-generation Antibody Market – Europe Analysis
9.1 Europe
- 9.1.1 Europe Next-generation Antibody Market Breakdown, by Key
Country, 2022 and 2028 (%)
- 9.1.1.1 Europe Next-generation Antibody Market – Revenue and
Forecast Analysis – by Country
- 9.1.1.1 UK:
Europe Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
- 9.1.1.1.1 UK: Europe Next-generation Antibody Market Breakdown, by Therapeutic Area
- 9.1.1.1.2 UK: Europe Next-generation Antibody Market Breakdown, by Technology
- 9.1.1.2 Germany:
Europe Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
- 9.1.1.2.1 Germany: Europe Next-generation Antibody Market Breakdown, by Therapeutic Area
- 9.1.1.2.2 Germany: Europe Next-generation Antibody Market Breakdown, by Technology
- 9.1.1.3 France:
Europe Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
- 9.1.1.3.1 France: Europe Next-generation Antibody Market Breakdown, by Therapeutic Area
- 9.1.1.3.2 France: Europe Next-generation Antibody Market Breakdown, by Technology
- 9.1.1.4 Russia:
Europe Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
- 9.1.1.4.1 Russia: Europe Next-generation Antibody Market Breakdown, by Therapeutic Area
- 9.1.1.4.2 Russia: Europe Next-generation Antibody Market Breakdown, by Technology
- 9.1.1.5 Italy:
Europe Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
- 9.1.1.5.1 Italy: Europe Next-generation Antibody Market Breakdown, by Therapeutic Area
- 9.1.1.5.2 Italy: Europe Next-generation Antibody Market Breakdown, by Technology
- 9.1.1.6 Rest of Europe:
Europe Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
- 9.1.1.6.1 Rest of Europe: Europe Next-generation Antibody Market Breakdown, by Therapeutic Area
- 9.1.1.6.2 Rest of Europe: Europe Next-generation Antibody Market Breakdown, by Technology
10. Competitive Landscape
10.1 Heat Map Analysis
10.2 Company Positioning and Concentration
11. Europe Next-generation Antibody Market Industry Landscape
11.1 Overview
11.2 Mergers and Acquisitions
11.3 Agreements, Collaborations, and Joint Ventures
11.4 New Product Launches
11.5 Expansions and Other Strategic Developments
12. Company Profiles
12.1 F. HOFFMANN-LA ROCHE LTD.
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 Seagen Inc.
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 Takeda Pharmaceutical Company Limited
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 Amgen Inc.
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 Pfizer Inc.
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 Catalent Inc
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 AstraZeneca
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
13. Appendix
13.1 About Business Market Insights
Get Free Sample For Europe Next-generation Antibody Market
